Concepedia

Lida A. Mina

LA

Statistics

Publications

31

Citations

4.2K

H-Index

22

Active since

2006

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Indiana University – Purdue University Indianapolis

University of California, Los Angeles

Texas Oncology

UCSF Helen Diller Family Comprehensive Cancer Center

Lida A. Mina is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, medicine, and pharmacology.

ORCID

Publications per year

2006–2024

31

Publications

31

Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation

Jennifer K. Litton, Hope S. Rugo, Johannes Ettl et al. · New England Journal of Medicine · 2018 · 2.2K citations · Full text

, , +14

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

Jennifer K. Litton, Sara A. Hurvitz, Lida A. Mina et al. · Annals of Oncology · 2020 · 394 citations · Full text

, , +14

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline <i>BRCA1/2</i> Mutations and Selected Sporadic Cancers

Johann S. de Bono, Ramesh K. Ramanathan, Lida A. Mina et al. · Cancer Discovery · 2017 · 383 citations · Full text

, , +13

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial

Johannes Ettl, Ruben G.W. Quek, Ki Hoon Lee et al. · Annals of Oncology · 2018 · 140 citations · Full text

, , +11

A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline <i>BRCA1/2</i> Mutations (ABRAZO)

Nicholas C. Turner, Melinda L. Telli, Hope S. Rugo et al. · Clinical Cancer Research · 2018 · 125 citations

, , +14

1–5 of 31